April 20, 2022

sedApta Group and Vineti partner to develop integrated digital supply chain and manufacturing solution for cell and gene therapies

Giessen, Germany and San Francisco, CA, April 20th 2022 – The sedApta Group, a global software provider specialized in innovative IT solutions for digital Supply Chain and Smart Manufacturing, and Vineti, the provider of the leading clinical-to-commercial digital platform for cell and gene therapy supply chain management, today announced a partnership to develop an integrated solution to automate end-to-end manufacturing for cell and gene therapies.

The non-exclusive partnership will create an integrated digital solution between leaders in smart manufacturing, digital supply chain management, Chain of Identity (COI) and Chain of Custody (COC), and cell and gene therapy workflows. The sedApta Suite provides an integrated set of modules for the planning, management, and optimization of business processes across supply chains for a variety of business verticals, including biopharmaceutical manufacturing. Vineti’s Personalized Therapy Management® (PTM) platform, purpose-built to manage cell and gene therapy workflows, offers an enterprise solution uniquely capable of orchestrating the singular workflow complexity of these transformative therapeutics.

“With this partnership, we will combine our expertise to offer a truly innovative solution for one of the newest fields of biopharmaceuticals,” said Michael Fatum, Director of sedApta GmbH. “This means that our cell and gene therapy customers, and the patients they serve, will be able to count on the type of advanced, ‘Industry 4.0’ approach that sedApta brings to all of its solutions in manufacturing execution and supply chain management.”

As part of this new partnership, sedApta and Vineti will be participating at the upcoming Supply Chain and Logistics for Cell Therapies Summit in Boston, MA from April 25-27.

“We’re very excited to work with sedApta to develop a new end-to-end solution for cell and gene therapy supply chains and manufacturing,” said Vineti CEO Ann Klein. “As the only company of our kind supporting both clinical-phase and commercial advanced therapies, we know what it takes to support these therapeutics at all phases of development. By partnering with sedApta, we’ll develop an integrated solution that truly optimizes the cell and gene therapy process.”

About sedApta Group

sedApta is an international Group formed from the aggregation of top technology companies based in Italy, Germany, France, UK and Brazil. Together we share over 25 years of experience in Manufacturing Operation Management and Supply Chain Management providing solutions able to accompany customers in the deployment of their products. Through its subsidiaries and partner network, sedApta has rapidly expanded to become a key player in the market of the innovative global supply chain digitization and Industry 4.0. Today, over 1,000 customers in more than 20 countries belonging to more than10 industry segments rely on our Products for the optimization of their extended Supply Chain.

The sedApta suite is a seamless, integrated suite of solutions, enabling planning, execution and optimization across all supply chain functions to maximize business results.

Our mission is to drive the continuous improvement of industrial processes through the introduction of new information technologies and a highly integrated suite of modules within existing infrastructures.

About Vineti

Vineti offers the first commercial, configurable cloud-based platform to expand patient access to life-saving cell and gene therapies. Vineti was co-founded by GE and the Mayo Clinic to solve the key challenges that patients, medical providers, biopharmaceutical companies, and regulators face in the delivery and commercialization of individualized therapies. Now a fully independent company, Vineti offers a digital platform of record to integrate logistics, supply chain management, manufacturing, and clinical data for personalized therapies. The Vineti Personalized Therapy Management® (PTM) platform aligns and orchestrates the advanced therapy process and improves product performance overall, supporting the full continuum of patient-specific therapies, including personalized cancer vaccines and autologous and allogeneic cell and gene therapies. Vineti is currently serving patients, healthcare providers, and researchers in hundreds of leading medical and manufacturing centers world-wide on behalf of a growing number of biopharmaceutical partners.

Media contact

sedApta GmbH contact information:
Ph.: +49 641 794 9710

Vineti contact information:
1AB Media for Vineti
Dan Budwick